IC
ERAS icon

Ikarian Capital’s Erasca ERAS Stock Holding History

Ikarian Capital’s Portfolio ERAS Stock Details ERAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-735,396
Closed -$2.74M – 183
2025
Q4 		$2.74M Buy
+735,396
New +$2.07M 0.21% 90

Other funds holding ERAS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Ikarian Capital's ERAS Position: Q1 2026 in Review

Ikarian Capital sold out of Erasca (ERAS) in Q1 2026, closing a stake of 735,396 shares — an estimated $2.74M sold.

Ikarian Capital first reported a position in ERAS in Q4 2025 and held it in 1 quarter. The position peaked at $2.74M in Q4 2025. 225 funds tracked by Wall St. Rank hold ERAS as of Q1 2026.

  • Ikarian Capital reported no remaining Erasca position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 735,396 Erasca shares in Q1 2026, an estimated $2.74M.
  • Ikarian Capital first reported a position in Erasca in Q4 2025 and held it in 1 quarter.
  • Ikarian Capital's Erasca position peaked at $2.74M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Erasca as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.